Anzeige
❌
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: 858523 | ISIN: JP3256000005 | Ticker-Symbol: KY4
Stuttgart
06.06.25 | 08:10
14,600 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
KYOWA KIRIN CO LTD Chart 1 Jahr
5-Tage-Chart
KYOWA KIRIN CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
14,70015,00017:30
14,70014,90017:27

Aktuelle News zur KYOWA KIRIN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting86GlobeNewswire (Europe)- CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups...
► Artikel lesen
MoFDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin's Ziftomenib4Insider Monkey
MoKura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML89GlobeNewswire (Europe)- New Drug Application based on positive results from the Phase 2 KOMET-001 trial - - FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 - - Potential first...
► Artikel lesen
23.05.Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 20257Insider Monkey
22.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting118GlobeNewswire (Europe)- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd - - Encore presentation planned at EHA 2025 Congress...
► Artikel lesen
KYOWA KIRIN Aktie jetzt für 0€ handeln
14.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress174GlobeNewswire (Europe)- Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th - - Updated dataset to be presented in oral presentation at EHA2025 Congress...
► Artikel lesen
18.04.Fierce Pharma Asia-The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant4FiercePharma
14.04.Kyowa Kirin constructs drug manufacturing facility in Japan2Pharmaceutical Technology
11.04.As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan2FiercePharma
08.04.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA222GlobeNewswire (Europe)SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, "Kura"), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug...
► Artikel lesen
12.03.Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis22PMLiVE
10.03.Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study7Benzinga.com
08.03.Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis404PR NewswireOngoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa...
► Artikel lesen
06.02.Kyowa Kirin GAAP EPS of ¥113.06, revenue of ¥495.56B5Seeking Alpha
05.02.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs176GlobeNewswire (Europe)- KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting - - NDA submission for ziftomenib on track...
► Artikel lesen
04.02.Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns2FiercePharma
30.01.Kyowa Kirin International: Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe494Business WireSecond- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia's National Health Insurance Fund (NHIF), effective as of 15th November 2024. ...
► Artikel lesen
27.12.24Dividendenbekanntmachungen (27.12.2024)16.752wallstreetONLINE (Dividenden) Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ADWAYS INC  JP3121970002  3 JPY  0,0182 EUR  AGC INC  JP3112000009  105 JPY  0,6373 EUR  ALERUS FINANCIAL CORPORATION  US01446U1034  0...
► Artikel lesen
17.12.24Für bessere Therapien gegen Blutkrebs: Spin-off Cimeio arbeitet mit Pharmakonzern Kyowa Kirin zusammen11Bionity.com
13.12.24Cimeio Therapeutics erhält bis zu 300 Millionen Dollar von Kyowa Kirin4punkt4.info
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1